Inclusion Criteria:

- Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is
metastatic or unresectable for which standard curative measures do not exist or are
no longer effective

- Eastern Cooperative Oncology Group (ECOG) performance status
- Life expectancy greater than 3 months

- Adequate organ and marrow function

- Written informed consent

- Use of acceptable methods of contraception during the course of the study and for 3
months after completion of study

- In the MTD expanded cohort: at least 20 subjects with metastatic and/or
advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical
resection with measurable disease as defined by RECIST

Exclusion Criteria:

- Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin
C within 6 weeks) before the first scheduled dose of XL184

- Administration of an investigational drug within 30 days of the first dose of XL184

- Subject has not recovered from adverse events due to investigational agents or other
medications administered more than 4 weeks before study enrollment

- Known brain metastases

- Uncontrolled intercurrent illness

- Pregnancy or breastfeeding

- Known HIV positive

- Known allergy or hypersensitivity to any of the components of the XL184 formulation